Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120%

In This Article:

Amidst a mixed performance in the Australian market, with sectors like IT and Energy facing downturns while Telecommunications showed resilience, investors continue to navigate through a landscape marked by fluctuating commodity prices and economic data. In such an environment, growth companies with high insider ownership can offer unique investment opportunities as these insiders often have a vested interest in the company's success, aligning their goals closely with those of shareholders.

Top 10 Growth Companies With High Insider Ownership In Australia

Name

Insider Ownership

Earnings Growth

Hartshead Resources (ASX:HHR)

13.9%

86.3%

Cettire (ASX:CTT)

28.7%

30.1%

Gratifii (ASX:GTI)

17%

112.4%

Acrux (ASX:ACR)

14.6%

115.3%

Doctor Care Anywhere Group (ASX:DOC)

28.4%

96.4%

Plenti Group (ASX:PLT)

12.8%

106.4%

Hillgrove Resources (ASX:HGO)

10.4%

45.4%

Change Financial (ASX:CCA)

26.6%

85.4%

Botanix Pharmaceuticals (ASX:BOT)

11.4%

120.9%

Liontown Resources (ASX:LTR)

16.4%

63.9%

Click here to see the full list of 91 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

Botanix Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★★

Overview: Botanix Pharmaceuticals Limited is an Australian company focused on the research and development of dermatology and antimicrobial products, with a market capitalization of approximately A$519.80 million.

Operations: The company generates revenue primarily from its activities in developing dermatology and antimicrobial products, totaling A$0.44 million.

Insider Ownership: 11.4%

Earnings Growth Forecast: 120.9% p.a.

Botanix Pharmaceuticals, while demonstrating robust projected growth with earnings expected to increase significantly and revenue forecasted to grow at 120.4% per year, faces challenges due to a short cash runway and recent shareholder dilution. Despite these concerns, the company is anticipated to become profitable within three years and boasts a very high projected Return on Equity of 43.9%. Moreover, Botanix recently detailed its commercial launch strategies for SofdraÔ as it approaches regulatory approval.

ASX:BOT Earnings and Revenue Growth as at Jun 2024
ASX:BOT Earnings and Revenue Growth as at Jun 2024

Mesoblast

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited, operating in Australia, the United States, Singapore, and Switzerland, focuses on developing regenerative medicine products with a market capitalization of approximately A$1.24 billion.


Waiting for permission
Allow microphone access to enable voice search

Try again.